Hainan Huluwa Pharmaceutical Group Co., Ltd. (SHA:605199)
China · Delayed Price · Currency is CNY 6.28
-0.16 (-2.48%)
Jun 11, 2026, 3:00 PM CST
SHA:605199 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 709.65 | 900.35 | 1,407 | 1,782 | 1,515 | 1,354 |
Other Revenue | 0.49 | 0.49 | 6.59 | 12.94 | - | - |
| 710.14 | 900.84 | 1,414 | 1,795 | 1,515 | 1,354 | |
Revenue Growth (YoY) | -44.51% | -36.27% | -21.26% | 18.49% | 11.91% | 16.54% |
Cost of Revenue | 560.87 | 656.2 | 744.53 | 892.85 | 644.31 | 546.54 |
Gross Profit | 149.27 | 244.63 | 669.02 | 902.33 | 870.74 | 807.25 |
Selling, General & Admin | 314.46 | 355.14 | 730.07 | 734.51 | 654.11 | 612.94 |
Research & Development | 89.9 | 93.86 | 202.08 | 113.66 | 105.66 | 100.43 |
Other Operating Expenses | 14.71 | 11.4 | -20.94 | 16.84 | 13.68 | 17.95 |
Operating Expenses | 436.52 | 483.99 | 915.29 | 880.59 | 773.21 | 734.55 |
Operating Income | -287.25 | -239.36 | -246.27 | 21.74 | 97.52 | 72.7 |
Interest Expense | -39.67 | -40.75 | -31.75 | -18.24 | -18 | -13.87 |
Interest & Investment Income | 0.55 | 0.5 | 10.11 | 1.34 | 2.01 | 3.77 |
Currency Exchange Gain (Loss) | - | - | - | 0 | - | - |
Other Non Operating Income (Expenses) | -1.38 | -1.92 | -1.06 | -1.34 | -1.08 | 0.02 |
EBT Excluding Unusual Items | -327.74 | -281.53 | -268.96 | 3.5 | 80.45 | 62.62 |
Impairment of Goodwill | -12.11 | -12.11 | - | - | - | - |
Gain (Loss) on Sale of Investments | -2.41 | -2.95 | - | -4.43 | -2.06 | -3.66 |
Gain (Loss) on Sale of Assets | 0.07 | -0.05 | 0.04 | -0.08 | -0.55 | -0.47 |
Asset Writedown | -6.89 | -0.63 | -0.86 | - | - | - |
Other Unusual Items | 28.58 | 28.61 | 0.62 | 28.04 | 19.38 | 23.18 |
Pretax Income | -320.5 | -268.67 | -269.17 | 27.03 | 97.23 | 81.66 |
Income Tax Expense | 16.73 | 15.66 | 0.35 | 10.05 | 12.49 | 12.11 |
Earnings From Continuing Operations | -337.23 | -284.33 | -269.52 | 16.97 | 84.74 | 69.56 |
Minority Interest in Earnings | -3.45 | -3.05 | -4.94 | -6.12 | 0.94 | 2.58 |
Net Income | -340.68 | -287.37 | -274.46 | 10.85 | 85.68 | 72.14 |
Net Income to Common | -340.68 | -287.37 | -274.46 | 10.85 | 85.68 | 72.14 |
Net Income Growth | - | - | - | -87.33% | 18.77% | -40.63% |
Shares Outstanding (Basic) | 401 | 399 | 398 | 362 | 408 | 401 |
Shares Outstanding (Diluted) | 401 | 399 | 398 | 362 | 408 | 401 |
Shares Change (YoY) | -0.04% | 0.34% | 9.97% | -11.35% | 1.81% | 5.55% |
EPS (Basic) | -0.85 | -0.72 | -0.69 | 0.03 | 0.21 | 0.18 |
EPS (Diluted) | -0.85 | -0.72 | -0.69 | 0.03 | 0.21 | 0.18 |
EPS Growth | - | - | - | -85.71% | 16.67% | -43.75% |
Free Cash Flow | 245.29 | 53.18 | -305.35 | -460.95 | -153.61 | -35.14 |
Free Cash Flow Per Share | 0.61 | 0.13 | -0.77 | -1.27 | -0.38 | -0.09 |
Dividend Per Share | - | - | - | 0.125 | - | - |
Gross Margin | 21.02% | 27.16% | 47.33% | 50.26% | 57.47% | 59.63% |
Operating Margin | -40.45% | -26.57% | -17.42% | 1.21% | 6.44% | 5.37% |
Profit Margin | -47.97% | -31.90% | -19.42% | 0.60% | 5.66% | 5.33% |
Free Cash Flow Margin | 34.54% | 5.90% | -21.60% | -25.68% | -10.14% | -2.60% |
EBITDA | -185.9 | -143.38 | -171.75 | 74.11 | 143.77 | 117.46 |
EBITDA Margin | -26.18% | -15.92% | -12.15% | 4.13% | 9.49% | 8.68% |
D&A For EBITDA | 101.34 | 95.98 | 74.52 | 52.37 | 46.25 | 44.76 |
EBIT | -287.25 | -239.36 | -246.27 | 21.74 | 97.52 | 72.7 |
EBIT Margin | -40.45% | -26.57% | -17.42% | 1.21% | 6.44% | 5.37% |
Effective Tax Rate | - | - | - | 37.19% | 12.84% | 14.83% |
Revenue as Reported | 710.14 | 900.84 | 1,414 | 1,795 | 1,515 | 1,354 |
Advertising Expenses | - | 131.35 | 446.81 | 443.11 | 452.11 | 426.22 |